关键词: 多发性骨髓瘤, 复发/难治性多发性骨髓瘤, 达雷妥尤单抗, 治疗结果, 不良反应

Abstract: Background　Multiple myeloma will relapse in the majority of such patients as there is no cure for it.Daratumumab，a CD38 human monoclonal antibody，has been reported by foreign studies to have significant clinical activity in relapsed or refractory multiple myeloma.However，there are limited data on its efficacy and toxicity profiles in Chinese patients.Objective　To investigate the clinical efficacy and safety of daratumumab in the treatment of patients with relapsed or refractory multiple myeloma.Methods　From October 2019 to June 2020，9 patients with relapsed or refractory multiple myeloma treated with daratumumab-based chemotherapy were selected from Department of Hematology，Beijing Jishuitan Hospital.Their clinical data，follow-up response and adverse reactions to daratumumab-based regimens were retrospectively analyzed.Results　Among the 9 patients，7 were available for response evaluation.Two（28.6%） achieved complete response，two（28.6%）achieved very good partial response，one（14.3%）achieved partial response，one（14.3%）achieved minimal response and one （14.3%） achieved stable disease.The overall response rate was 71.4%（5/7）.The most common hematological adverse events were thrombocytopenia，neutropenia and lymphopenia，with the incidences of grade 3 and 4 of 33.3%（3/9）and 33.3%（3/9）and 55.6%（5/9），respectively.The percentage of infusion related reactions of daratumumab was 44.4%（4/9）.Conclusion Daratumumab is highly effective and safe in the treatment of relapsed or refractory multiple myeloma.

Key words: Multiple myeloma, Relapsed or refractory multiple myeloma, Daratumumab, Treatment outcome, Adverse events